

ENDOCRINE SYSTEM



LECTURE 7 :

Metabolic changes in diabetes mellitus

Objectives:

- ▶ Background
- ▶ Diagnostic criteria for DM
- ▶ Metabolic changes in DM
- ▶ Mechanisms of diabetic complications

Abbreviations:

- DM → diabetes mellitus
- T1DM → type 1 diabetes mellitus
- T2DM → type 2 diabetes mellitus
- FPG → fasting plasma glucose
- OGTT → oral glucose tolerance test
- A1C → glycated hemoglobin
- VEGF → vascular endothelial growth factor

* The reference ranges of the normal values will be given in exam

Comparison of type 1 and type 2 DM

	Type 1	Type 2
Age of onset	Childhood	Adult
Symptoms develop	Rapidly	Gradually
Defect & deficiency	Beta cells are destroyed	Insulin resistance + inability of beta cells to produce enough insulin
ketosis	common	Rare
Plasma insulin	low	A-high early in disease B-low in disease of long duration
Acute complication	Ketoacidosis	Hyperosmolar coma
Genetic predisposition	Moderate	Very strong
Use of oral hypoglycemic	Unresponsive	Responsive
Treatment	Insulin is always necessary	Diet, exercise, oral hypoglycemic, +/- insulin

Natural course

Type 1 DM

Type 2 DM

1-exposure to a virus or toxin may start beta cell destruction =>
↓ Insulin production.
2-insulin secretory capacity falls below a threshold & the symptoms appears

1- Obese individuals develop **insulin resistance** which may precede the development of DM.
2- They show Compensatory hyperinsulinemia in early stages
3- β-cell dysfunction occur marked by ↓insulin and worsening hyperglycemia

1: Fasting is defined as no caloric intake for at least 8 hrs

Criteria for diagnosis of DM:

1- Categories of **increased risk** for diabetes

FPG¹=5.6-6.9 mmol/l

OGTT=7.8-11 mmol/l

A1C= 5.7-6.4%

2- Diagnosis of diabetes

FPG > 7 mmol/l

OGTT > 11.1 mmol/l



A1C > 6.5%

Random plasma glucose > 11.1 mmol/l

+ Hyperglycemia symptoms

Hemoglobin A1C:

- Is the result of non enzymatic covalent glycosylation of hemoglobin
- Assays for A1C has to be standardized according to the National Glycohemoglobin Standardization Program (NGSP).



Metabolic changes in DM

CHO:

- 1- ↓ glucose uptake in muscle & adipose tissues
- 2- ↑ glycogenolysis
- 3 ↑ gluconeogenesis


Lipid:

- 1- ↑ lipolysis
- 2- ↑ fatty acid oxidation
- 3- ↑ production of ketone bodies (more in T1DM)

Protein:


- 1- ↓ protein synthesis
- 2- ↑ protein degradation

Mechanisms of Increase Hepatic Glucose Output




Mechanisms of Decrease of Peripheral Glucose Uptake


1/ muscle



2/ Adipose Tissue



Complication of DM



Advanced Glycosylation End Products (AGEs)

Chronic hyperglycemia → non-enzymatic combination between **excess glucose & amino acids in proteins** → formation of AGEs

AGEs may cross link with **collagen** → **microvascular complications**

The interaction between AGEs and their receptor (RAGE) may generate **reactive oxygen species (ROS)** → **inflammation**

Microvascular Complications

-Chronic hyperglycemia →

1- ↑ Advanced Glycation End products (AGEs) of essential cellular proteins → **cellular defects**

2- ↑ Intracellular sorbitol → ↑ **cell osmolality** → **cellular swelling**

3- ↑ Reactive Oxygen Species (ROS) → **oxidative stress** → **cell damage**

Polyol pathway

Glucose is metabolized to sorbitol within the cells by **aldose reductase**

The role of sorbitol in the pathogenesis of diabetic complications is uncertain.

Hypotheses are:

1- During sorbitol production, consumption of NADPH → **oxidative stress**.

2- Sorbitol accumulation →

A- Increase the intracellular osmotic pressure → **osmotic drag of fluid from extracellular space** → **cell swelling**

B- Alteration in the activity of PKC → **altered VEGF¹ activity** → **altered vascular permeability**

1-Vascular endothelial growth factor

Diabetic Retinopathy

A progressive microvascular complication of DM, affecting the retina of the eye

It cause **blindness**

Its prevalence ↑ with increasing duration of disease in both type 1 & 2 DM

After **20 years** of the disease:

Is present in almost **all** T1DM

Is present in **50 – 80%** of T2DM

Diabetic Nephropathy

- ▶ Occurs in both type 1 & type 2 DM
- ▶ The earliest clinical finding of diabetic nephropathy is **microalbuminuria**:
 - ▶ (the persistent excretion of small amounts of albumin (30-300 mg per day) into the urine)
- ▶ Microalbuminuria is an important predictor of progression to **proteinuria**:
 - (the persistent excretion of >300 mg albumin per day into the urine)
- ▶ Once proteinuria appears, there is a steady ↓ in the glomerular filtration rate (GFR)
- ▶ Finally, **end-stage renal disease** occurs

Diabetic Neuropathy

- Loss of both myelinated and unmyelinated nerve fibers

- Occurs in both type 1 & type 2 DM

- It correlates with the duration of DM & with glycemic control

Summary

- T1DM results from destruction of beta cells of the pancreas while T2DM is due to the development of insulin resistance.
- **Genetics, Obesity , sedentary lifestyle and aging** are the factors which may contribute in the development of insulin resistance.
- Criteria for diagnosis of DM includes assessment of **FPG - OGTT - A1C** .
- **Complications of DM are classified into :**
 - Macrovascular (CVS diseases)
 - microvascular (Neuropathy , Retinopathy)
- General Mechanisms for Diabetic Microvascular Complications:
 - ✓ **↑ Advanced Glycation End products (AGEs) of essential cellular proteins → cellular defects**
 - ✓ **↑ Intracellular sorbitol → ↑ cell osmolality → cellular swelling**
 - ✓ **↑ Reactive Oxygen Species (ROS) → oxidative stress → cell damage**
- The earliest clinical finding of diabetic nephropathy is **microalbuminuria** then progression to **proteinuria** and **decrease GFR** and may end with **end-stage renal disease** .

TEST YOURSELF!

1. Regarding diabetic retinopathy, which one is incorrect:

- A. Higher risk in type 1.
- B. Microvascular disease contributes in the progression of diabetic retinopathy.
- C. Never happens in type 2.
- D. Common complication.

2. Microalbuminuria is a complication occurs in:

- A. Diabetic retinopathy.
- B. Diabetic nephropathy.
- C. Diabetic neuropathy.
- D. Diabetic ketoacidosis.

3. Which one of the following cut-off points of Hemoglobin A1C is used to diagnose diabetes?

- A. Less than 6.5 %.
- B. More than 6.5 %.
- C. More than 5.6 % .
- D. Less than 5.6 % .

4. All of the following are major metabolic changes seen in diabetes mellitus except:

- A. Glycogenolysis.
- B. Increased protein synthesis.
- C. Increase lipolysis.
- D. Increase production of ketone bodies.

5. Chronic hyperglycemia will lead to non-enzymatic combination between excess glucose and amino acids in proteins which is known as:

- A. Polyol pathway.
- B. ROS.
- C. Advanced Glycosylation End Products.
- D. None of the above.

6. Microvascular complication seen in DM, may result from cross linkage between:

- A. AGEs and Amyloid.
- B. Cytokines and IL-1.
- C. AGEs and Interferon Alfa.
- D. AGEs and Collagen.

1-C

2-B

3-B

4-B

5-C

6-D

TEST YOURSELF!

7. Sorbitol accumulation in retina, nerves, and kidney is responsible for the diabetic complication, because these tissues do not have the following enzyme:

- A. Sorbitol hydroxylase.
- B. Aldos Reductase.
- C. Sorbitol dehydrogenase.
- D. DGlucokinase.

8. The earliest clinical finding of diabetic nephropathy is:

- A. Microalbuminuria.
- B. Macroalbuminuria.
- C. Proteinuria.
- D. Albumin excretion is normal.

9. Testing the levels of which one of the following estimates glycemic control in the last 1-2 months:

- A. FBG.
- B. HBA1C.
- C. FFA.
- D. Insulin.

10. Which one of the following is a metabolic effect of insulin:

- A. ↑ Lipolysis.
- B. ↑ protien synthesis.
- C. ↑ Glycogenolysis.
- D. ↓ Lipolysis.

Answers :

7-C 8-A 9-B 10-D

THANK YOU ...

DONE BY :
HAJAR ALOTAIBI
AHMED ALQAHTANI
KHALID ALSUHAIBANI

REVISED BY :
SARA ALDOKHAYEL
MAHA ALRAJHI
MOHAMMED ALNAFISAH

